Novel biomarkers identified for prostate cancer in non-blacks

Novel biomarkers identified for prostate cancer in non-blacks

(HealthDay)—Novel biomarkers have been identified that may have utility for predicting prostate cancer in non-African-American men, according to a study published in the July issue of The Journal of Urology.

Padraic G. O'Malley, M.D., from the Weill Cornell Medical College in New York City, and colleagues examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate in a cohort of 718 men who were part of the Early Detection Research Network (72 African-American men).

The researchers found that when combined with the Prostate Cancer Prevention Trial Risk Calculator, prostate cancer antigen 3 (PCA3) and transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion (T2ERG) added utility for the prediction of prostate cancer and clinically-significant prostate cancer. This utility was only seen in non-African-American men, with significant increases in the area under the curve values for prostate cancer and clinically-significant for PCA3 (0.64 to 0.75 and 0.69 to 0.77, respectively) and T2ERG (0.64 to 0.74 and 0.69 to 0.73, respectively). No added benefit was seen with the addition of biomarkers for African-American men.

"As novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts," the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry.


Explore further

Combined urine test for T2:ERG, PCA3 ups prostate CA detection

More information: Abstract
Full Text
Editorial (subscription or payment may be required)
Journal information: Journal of Urology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Novel biomarkers identified for prostate cancer in non-blacks (2017, June 20) retrieved 15 December 2019 from https://medicalxpress.com/news/2017-06-biomarkers-prostate-cancer-non-blacks.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments